NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

TSX · Drug Manufacturers - Specialty & Generic · CAD

HLS Therapeutics Inc. (HLS.TO) Stock Analysis

HLS Therapeutics Inc. (HLS.TO) is a Drug Manufacturers - Specialty & Generic stock listed on TSX and quoted in Canadian Dollar.

HLS.TO

CA$3.70

+CA$0.10 (+2.78%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare HLS.TO with… →

HLS.TO Key Statistics

As of Sep 4, 2026
Trading
Open
CA$3.65
Previous Close
CA$3.60
Day's Range
3.60–3.77
52-Week Range
0.00–5.77
Volume
68.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.83
Valuation
Market Cap
CA$114.46M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.04
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.38
Financials (FY)
Revenue (FY)
CA$55.50M−1.98%
Net Income (FY)
−CA$12.43M
Profit marginThe share of revenue left as profit after all costs and taxes.
−15.24%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
30.94M
1-Year Return
−33.09%
Dividend and dates
Earnings Date
November 12, 2026
Avg Volume
60.70K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

HLS.TO Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−23.24%
2025+22.65%
2024−0.51%
2023−59.25%
2022−33.41%
2021−15.74%
2020−28.62%
2019+76.29%
2018 (partial year)+27.39%

As of September 4, 2026.

HLS.TO Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025CA$55.50M−CA$12.43M−22.4%
2024CA$56.62M−CA$19.66M−34.7%
2023CA$63.07M−CA$27.53M−43.6%
2022CA$61.47M−CA$23.60M−38.4%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025CA$55.50MCA$45.42M−CA$4.11M−CA$12.43M−22.4%
2024CA$56.62MCA$47.62M−CA$7.69M−CA$19.66M−34.7%
2023CA$63.07MCA$55.45M−CA$10.35M−CA$27.53M−43.6%
2022CA$61.47MCA$56.49M−CA$13.50M−CA$23.60M−38.4%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

HLS.TO Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 103 stocks
MetricHLS.TODrug Manufacturers - Specialty & Generic medianvs median
P/S ratio2.042.3011% below
Profit margin−15.24%−3.14%12.1 pts below

Medians across 103 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values HLS Therapeutics Inc. (HLS.TO) at CA$114.46M. It is classified in the Drug Manufacturers - Specialty & Generic industry, within the Healthcare sector. Headcount on file is 85.

The 52-week range on file runs from CA$0.00 to CA$5.77. The most recent close on file for HLS.TO is CA$3.70, dated September 4, 2026. That is +CA$0.10 (+2.78%) against the previous close. The latest close sits 369,900% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of CA$55.50M. That is −1.98% against the prior fiscal year, when revenue was CA$56.62M. The same year closed with a net loss of CA$12.43M. Profit margin runs at −15.24%. That is 12.1 percentage points below the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to −0.38.

Across the 4 fiscal years on file, revenue moves from CA$61.47M in 2022 to CA$55.50M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 2.04 times revenue. On price-to-sales that is 11.37% below the Drug Manufacturers - Specialty & Generic median of 2.3. The medians here are taken across 103 Drug Manufacturers - Specialty & Generic companies that report the metric.

The trailing one-year price return is −33.09%. Across 5 years the annualized return works out at −27.39%. The reported beta is 0.83. Annualized volatility over the trailing 8 years is 46.85%.

Growth & Income

The record shows no dividend for HLS.TO.

Across the complete calendar years on file, 2019 returned +76.29% and 2023 returned −59.25%. Of the 7 complete calendar years on file, 2 finished higher. So far in 2026 the price is −23.24%.

Peer Comparison

HLS Therapeutics Inc. (HLS.TO) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
HLS Therapeutics Inc. HLS.TO CA$114.46M —
Takeda Pharmaceutical Company Limited TAK CA$58.92B —
Teva Pharmaceutical Industries Limited TEVA CA$42.37B 60.6
Haleon plc HLN CA$42.22B 20.0

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 19.3x. HLS Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$58.92B

 TEVA

Teva Pharmaceutical Industries Limited

$42.37B

 HLN

Haleon plc

$42.22B

 ZTS

Zoetis Inc.

$31.33B

 UTHR

United Therapeutics Corporation

$20.91B

 VTRS

Viatris Inc.

$19.39B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About HLS Therapeutics Inc.

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders and cardiovascular disease in Canada, the United States, and internationally. The company offers Clozaril (clozapine tablets), an atypical antipsychotic to manage symptoms of treatment-resistant schizophrenia; CSAN Pronto device, which enhances and simplifies the mandatory safety blood monitoring process for patients that are prescribed Clozaril; Nilemdo, a bempedoic acid product for cardiovascular risk reduction; Nexlizet, a bempedoic acid and ezetimibe product for cardiovascular risk reduction; and Vascepa, an icosapent ethyl capsule for the treatment of cardiovascular disease. It also distributes MyCare psychiatry lab assays, which are a line of tests that can be processed on analyzers used in laboratory systems to measure the blood levels of the most common antipsychotic drugs, including clozapine, risperidone, quetiapine, aripiprazole, olanzapine, and paliperidone; and MyCare Insite, a point-of-care device that requires only a single drop of blood taken by a finger stick to measure patient drug levels. In addition, the company holds royalty interest in Takeda's Obizur, a porcine recombinant Factor VIII for acquired Hemophilia A. It serves wholesalers and institutions. HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.

Visit website →